339 related articles for article (PubMed ID: 15833141)
1. Altered expression of membrane-bound and soluble CD95/Fas contributes to the resistance of fibrotic lung fibroblasts to FasL induced apoptosis.
Bühling F; Wille A; Röcken C; Wiesner O; Baier A; Meinecke I; Welte T; Pap T
Respir Res; 2005 Apr; 6(1):37. PubMed ID: 15833141
[TBL] [Abstract][Full Text] [Related]
2. Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis.
Huerta-Yepez S; Vega M; Garban H; Bonavida B
Clin Immunol; 2006 Sep; 120(3):297-309. PubMed ID: 16784892
[TBL] [Abstract][Full Text] [Related]
3. Higher susceptibility to Fas ligand induced apoptosis and altered modulation of cell death by tumor necrosis factor-alpha in periarticular tenocytes from patients with knee joint osteoarthritis.
Machner A; Baier A; Wille A; Drynda S; Pap G; Drynda A; Mawrin C; Bühling F; Gay S; Neumann W; Pap T
Arthritis Res Ther; 2003; 5(5):R253-61. PubMed ID: 12932288
[TBL] [Abstract][Full Text] [Related]
4. Increased cell surface Fas expression is necessary and sufficient to sensitize lung fibroblasts to Fas ligation-induced apoptosis: implications for fibroblast accumulation in idiopathic pulmonary fibrosis.
Wynes MW; Edelman BL; Kostyk AG; Edwards MG; Coldren C; Groshong SD; Cosgrove GP; Redente EF; Bamberg A; Brown KK; Reisdorph N; Keith RC; Frankel SK; Riches DW
J Immunol; 2011 Jul; 187(1):527-37. PubMed ID: 21632719
[TBL] [Abstract][Full Text] [Related]
5. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
6. Fas mediates apoptosis and oxidant-induced cell death in cultured hRPE cells.
Jiang S; Wu MW; Sternberg P; Jones DP
Invest Ophthalmol Vis Sci; 2000 Mar; 41(3):645-55. PubMed ID: 10711676
[TBL] [Abstract][Full Text] [Related]
7. Activation-induced T cell death: resistance or susceptibility correlate with cell surface fas ligand expression and T helper phenotype.
Oberg HH; Lengl-Janssen B; Kabelitz D; Janssen O
Cell Immunol; 1997 Oct; 181(1):93-100. PubMed ID: 9344501
[TBL] [Abstract][Full Text] [Related]
8. Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus.
Xue C; Lan-Lan W; Bei C; Jie C; Wei-Hua F
Cell Immunol; 2006 Feb; 239(2):121-8. PubMed ID: 16808908
[TBL] [Abstract][Full Text] [Related]
9. Fas/Fas ligand interactions are involved in ultraviolet-B-induced human lymphocyte apoptosis.
Caricchio R; Reap EA; Cohen PL
J Immunol; 1998 Jul; 161(1):241-51. PubMed ID: 9647230
[TBL] [Abstract][Full Text] [Related]
10. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
Viard-Leveugle I; Veyrenc S; French LE; Brambilla C; Brambilla E
J Pathol; 2003 Oct; 201(2):268-77. PubMed ID: 14517844
[TBL] [Abstract][Full Text] [Related]
11. Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection.
Raghuraman S; Abraham P; Daniel HD; Ramakrishna BS; Sridharan G
J Clin Virol; 2005 Sep; 34(1):63-70. PubMed ID: 16087126
[TBL] [Abstract][Full Text] [Related]
12. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment.
Tinazzi E; Puccetti A; Gerli R; Rigo A; Migliorini P; Simeoni S; Beri R; Dolcino M; Martinelli N; Corrocher R; Lunardi C
Int Immunol; 2009 Mar; 21(3):237-43. PubMed ID: 19181929
[TBL] [Abstract][Full Text] [Related]
13. Soluble Fas ligand induces epithelial cell apoptosis in humans with acute lung injury (ARDS).
Matute-Bello G; Liles WC; Steinberg KP; Kiener PA; Mongovin S; Chi EY; Jonas M; Martin TR
J Immunol; 1999 Aug; 163(4):2217-25. PubMed ID: 10438964
[TBL] [Abstract][Full Text] [Related]
14. Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure.
Nakae H; Narita K; Endo S
J Crit Care; 2001 Jun; 16(2):59-63. PubMed ID: 11481600
[TBL] [Abstract][Full Text] [Related]
15. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients.
Erdoğan B; Uzaslan E; Budak F; Karadağ M; Ediger D; Oral B; Göral G; Ege E; Gözü O
Tuberk Toraks; 2005; 53(2):127-31. PubMed ID: 16100648
[TBL] [Abstract][Full Text] [Related]
16. Analysis of cytotoxic T lymphocytes and Fas/FasL in Japanese patients with non-small cell lung cancer associated with HLA-A2.
Yoshimura C; Nomura S; Kanazawa S; Kuwana M; Muramatsu M; Yamaguchi K; Fukuhara S
J Cancer Res Clin Oncol; 2002 Nov; 128(11):581-8. PubMed ID: 12458337
[TBL] [Abstract][Full Text] [Related]
17. Balanced regulation of mRNA production for Fas and Fas ligand in lymphocytes from centenarians: how the immune system starts its second century.
Pinti M; Troiano L; Nasi M; Bellodi C; Ferraresi R; Mussi C; Salvioli G; Cossarizza A
Circulation; 2004 Nov; 110(19):3108-14. PubMed ID: 15505087
[TBL] [Abstract][Full Text] [Related]
18. Resistance to CD95 (APO-1/Fas)-mediated apoptosis in human renal cell carcinomas: an important factor for evasion from negative growth control.
Gerharz CD; Ramp U; Déjosez M; Mahotka C; Czarnotta B; Bretschneider U; Lorenz I; Müller M; Krammer PH; Gabbert HE
Lab Invest; 1999 Dec; 79(12):1521-34. PubMed ID: 10616203
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the morphological and biochemical changes in normal human lung fibroblasts and fibroblasts derived from lungs of patients with idiopathic pulmonary fibrosis during FasL-induced apoptosis.
Moodley YP; Caterina P; Scaffidi AK; Misso NL; Papadimitriou JM; McAnulty RJ; Laurent GJ; Thompson PJ; Knight DA
J Pathol; 2004 Apr; 202(4):486-95. PubMed ID: 15095276
[TBL] [Abstract][Full Text] [Related]
20. FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer.
Nadal C; Maurel J; Gallego R; Castells A; Longarón R; Marmol M; Sanz S; Molina R; Martin-Richard M; Gascón P
Clin Cancer Res; 2005 Jul; 11(13):4770-4. PubMed ID: 16000573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
